SRC
CDTX

Shufro Rose & Co’s Cidara Therapeutics CDTX Stock Holding History

Shufro Rose & Co’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-521
Closed -$5K – 336
2022
Q2 		$5K Hold
521
– – ﹤0.01% 320
2022
Q1 		$9K Buy
+521
New +$8.84K ﹤0.01% 335

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
DMKJ
David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Shufro Rose & Co's CDTX Position: Q3 2022 in Review

Shufro Rose & Co sold out of Cidara Therapeutics (CDTX) in Q3 2022, closing a stake of 521 shares — an estimated $5K sold.

Shufro Rose & Co first reported a position in CDTX in Q1 2022 and held it in 2 quarters. The position peaked at $9K in Q1 2022. 42 funds tracked by Wall St. Rank hold CDTX as of Q3 2022.

  • Shufro Rose & Co reported no remaining Cidara Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Shufro Rose & Co sold 521 Cidara Therapeutics shares in Q3 2022, an estimated $5K.
  • Shufro Rose & Co first reported a position in Cidara Therapeutics in Q1 2022 and held it in 2 quarters.
  • Shufro Rose & Co's Cidara Therapeutics position peaked at $9K in Q1 2022.
  • 42 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q3 2022.

Based on Shufro Rose & Co's 13F filing for Q3 2022, filed 24 Oct 2022.